FGFR3 is identified as a major differential regulator of bone formation and may serve as a novel therapeutic target for diseases affecting cartilage-to-bone transition, such as poor fracture healing.
No takes yet. Share an insight, caveat, or question.
Scalco et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: